Genentech Sustainability Profile
Genentech, a member of the Roche Group, is a pioneering biotechnology company headquartered in South San Francisco, US. Founded in 1976, Genentech has been at the forefront of the biotechnology industry, focusing on the development of innovative medicines for serious medical conditions. The company is renowned for its contributions to oncology, immunology, and neuroscience, with a portfolio that includes groundbreaking therapies such as Herceptin and Avastin. With a commitment to research and development, Genentech has achieved numerous milestones, including the first-ever recombinant DNA product approved by the FDA. Its unique approach to drug development, combining cutting-edge science with a patient-centric philosophy, has solidified its position as a leader in the biopharmaceutical market. Genentech continues to set benchmarks in the industry, driving advancements that improve patient outcomes globally.
DitchCarbon Score
How does Genentech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genentech's score of 40 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genentech's reported carbon emissions
In 2019, Genentech, headquartered in the US, reported total carbon emissions of approximately 140,550,000 kg CO2e, encompassing Scope 1, 2, and 3 emissions. The breakdown includes Scope 1 emissions of about 61,780,000 kg CO2e, primarily from stationary combustion (about 61,780,000 kg CO2e), mobile combustion (about 10,913,000 kg CO2e), process emissions (about 1,178,000 kg CO2e), and fugitive emissions (about 3,242,000 kg CO2e). Scope 2 emissions totalled approximately 63,436,000 kg CO2e, mainly from purchased electricity. Scope 3 emissions were significant, with business travel contributing about 55,446,000 kg CO2e and employee commuting accounting for about 18,154,000 kg CO2e. Genentech has not publicly disclosed specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The emissions data is cascaded from its parent company, Roche Holding AG, indicating a corporate family relationship that influences its sustainability reporting. Overall, Genentech's commitment to addressing climate change is evident through its comprehensive emissions reporting, although specific reduction strategies remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2004 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 54,533,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 21,308,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Genentech's Industry?
How Carbon Intensive is Genentech's Location?
Genentech's Scope 3 Categories Breakdown
Genentech's Scope 3 emissions, which increased by 12% last year and increased by approximately 245% since 2004, demonstrating supply chain emissions tracking. A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 34% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 75% of Scope 3 emissions.
Top Scope 3 Categories
Genentech's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genentech has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
